ADLM 2025 Recap: Innovation, Collaboration, and a Look Ahead
One of the largest clinical laboratory conferences, ADLM 2025, just wrapped up after five packed days of workshops, educational sessions, roundtables, and a bustling exhibit hall large enough to count as a step challenge just walking from one end to the other. The event brought together more than 16,000 laboratory medicine professionals to explore the latest data, tackle emerging challenges, and shape the future of diagnostics.
This marked the second year MDC Associates exhibited at the show. In addition to sharing our scientific and regulatory expertise, we also hosted a well-needed ice cream break and a rooftop mixer that brought together diverse groups in the field for relaxed, meaningful conversations.
The State of Diagnostics
A key theme this year and something MDC continues to watch closely is the diagnostic market’s resilience amid global uncertainty. Tariffs, political shifts, and evolving regulations are influencing the landscape, yet the market is rebounding, likely returning to pre-pandemic growth rates of about 4 percent annually.
One of the clearest trends is the rise of molecular Point of Care (POC) testing, which is steadily replacing rapid lateral flow devices. This shift is fueled by higher performance, expanding FDA approvals, and increasingly competitive pricing, making molecular POC more accessible across care settings.
Highlights from the Expo Floor
With one of the largest exhibitor halls in laboratory science, ADLM remains a premier venue to see where the industry is headed. This year’s standout topics included a growing emphasis on biomarker testing from UTIs to Alzheimer’s disease, a spotlight on women’s health, advancements in rapid antimicrobial susceptibility testing, emerging developments in digital imaging including pathology, Gram stain interpretation, and parasitology, and widespread integration of AI technologies for lab workflow optimization, specimen accessioning and aliquoting, image analysis, and biomarker discovery.
While moving from innovation to patient care can take over a decade for novel diagnostics, the collaborative energy at ADLM made it clear that the field is advancing with purpose.
Partnering with MDC Associates
Bringing diagnostics to market is no small feat. It requires cross-disciplinary expertise to navigate product development, optimization, regulatory pathways, clinical trials, and commercialization.
With over 30 years of experience and a strong network of collaborators, MDC Associates helps innovators of all sizes bring their diagnostics from concept to patient. Whether you are developing your first assay or scaling your platform, we are ready to support your journey.
Let’s start a conversation and explore how we can help bring your innovation to life.
Why MDC Associates?
- Accelerated Path to Market: Over 35 years of IVD expertise across a broad range of technologies and applications, guiding you through regulatory and clinical processes efficiently.
- Regulatory Expertise with Continuous FDA Engagement: Our established, positive relationship with the FDA helps you navigate submissions like Pre-subs, 510(k), De Novo, and PMAs smoothly.
- Practical Quality Expertise: We help you achieve your quality objectives without overwhelming your team with too much too soon. From eQMS to MDSAP and ISO audits, get expert advice and hands-on support.
- Extensive Clinical Site Network: Access a trusted network experienced in supporting high-complexity assays, CLIA-waived tests, and OTC diagnostics, providing fast and reliable performance validation.
- Your Trusted IVD CRO: Beyond strategy, we work as part of your team to execute critical steps in regulatory submissions, clinical trials, and quality systems compliance.
